Francesco Zaja

35PUBLICATIONS
125CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityHaematological tumoursPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (35)

|Mar 28, 2026
Early Ibrutinib Dose Modifications in CLL: A Post Hoc Analysis of the Real-World EVIdeNCE Study.

Stefano Molica, Potito Rosario Scalzulli, Lydia Scarfò

|Mar 25, 2026
Beyond mechanisms: toward patient-centered choices in BTKi-venetoclax fixed-duration therapy for CLL.

Francesca R Mauro, David Allsup, Stefano Molica

|Mar 10, 2026
Incidence of severe COVID-19 in patients with chronic lymphocytic leukaemia or indolent B-cell non-Hodgkin lymphoma who received vaccination and pre-exposure prophylaxis with tixagevimab and cilgavimab in Italy: An observational study by the GIMEMA working party on chronic lymphoproliferative disorders and by the Fondazione Italiana Linfomi.

Gian Matteo Rigolin, Stefano Soddu, Riccardo Dondolin

|Jan 28, 2026
Key Indications for Passive Immune Prophylaxis Against SARS-CoV-2 Infection in Malignant Hematological Disorders: An Analytic Hierarchy Process by an Ad Hoc Italian Expert Panel.

Monia Marchetti, Giovanni Barosi, Francesco Passamonti

|Sep 19, 2025
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study.

Andrea Visentin, Enrico Gaffo, Moritz Fürstenau

|Jun 25, 2025
Richter transformation in diffuse large B-cell lymphoma in patients with chronic lymphocytic leukemia receiving ibrutinib: risk factors and outcomes.

Sara Pepe, Candida Vitale, Diana Giannarelli

Pageof 6

Frequent Collaborators

12 joint publications

Luca Laurenti

12 joint publications

Andrea Visentin

10 joint publications

Gianluigi Reda

9 joint publications

Paolo Sportoletti